Menu Close Menu

    Seraccess®: Disruptive Technology for Monitoring Critical Blood Parameters

    In its MedTech division, Securecell is proudly developing Seraccess®, an innovative technology that fully automates the high-frequency collection, processing, and analysis of blood using next generation microfluidics for the monitoring and controlling of critical blood parameters using the smallest blood sample possible. 

    Seraccess® Innovation

    Seraccess® innovation begins with an ultra precise / fully automated Glucose ICU monitor and ends with a fully miniaturized / fully mobile artificial pancreas device for personalized life-changing glucose control.

    LEARN MORE

    • img8
      Seraccess® AGM / AXM Automated Glucose Monitoring for Hospital Care

      Seraccess® AGM / AXM Automates Glucose measurement every 15 min. to monitor, detect and treat dysglycemia in patients using only 2-3ml of blood per day.

      READ MORE
    • img7
      Seraccess® ONE / NEXTRA APDS (Artificial Pancreas Device System)

      A breakthrough wearable Artificial Pancreas Device System providing the highest quality automated care for patients suffering from severe glycemic dysregulation.

      READ MORE

    SERACCESS® MILESTONES

    • SERAPORT - TAKING TRANSDERMAL PORTS TO THE NEXT LEVEL

      Making sampling of minute amounts of blood possible

      Learn more
    • THE BENEFITS OF THE INTRAVENOUS PATHWAY - PART I

      Improving Time-in-Range not only in the STRECHTED RANGE (70-180mg/dl), but also in the HEALTHY RANGE (70-140mg/dl) ?

      Learn more
    • THE BENEFITS OF THE INTRAVENOUS PATHWAY - PART II

      Does measurement delay have a negative impact on Time-in-Range (70-140mg/dl) ?

      Learn more
    • THE LONG-TERM RELIABILITY OF SERACCESS’ AUTOMATED DILUTION PROCESS.

      Does the Seraccess® automated dilution process perform reliably in the long term?

      Learn more
    • THE BENEFITS OF THE INTRAVENOUS PATHWAY - PART III

      How does the Seraccess® blood glucose measurement perform in healthy subjects when compared to Cobas C111?

      Learn more
    • THE BENEFITS OF THE INTRAVENOUS PATHWAY - PART IV

      How does the Seraccess® blood glucose measurement compare to state-of-the-art CGM?

      Coming Soon

    • THE BENEFITS OF THE INTRAVENOUS PATHWAY - PART V

      How does the Seraccess® blood glucose measurement perform in healthy subjects when compared to YSI?

      Learn more
    • THE QUALITY OF SERACCESS®’ CONTINUOUS AUTOMATED BLOOD SAMPLING VIA AN EXISTING CATHETER. PART I

      Does Seraccess®’s automatic blood sampling, including sample preparation using the silicon membrane developed and patented by Securecell, work in vitro in a regulated blood circuit?

      Learn more
    • THE BENEFITS OF THE INTRAVENOUS PATHWAY - PART VI

      How does the Seraccess® blood glucose measurement perform in subjects with type 1 diabetes when compared to Cobas C111?

      Learn more
    • THE QUALITY OF SERACCESS®’ CONTINUOUS AUTOMATED BLOOD SAMPLING VIA AN EXISTING CATHETER. PART II

      Does Seraccess®’s continuous automatic blood sampling work in vivo on live sheep?

      Learn more
    • THE COMBINATION OF CONTINUOUS AUTOMATED BLOOD SAMPLING WITH THE BLOOD GLUCOSE MEASUREMENT

      Does Seraccess®'s automatic blood sampling, including sample preparation using the silicon membrane developed and patented by Securecell and the blood glucose measurement, work in vivo on live sheep?

      Learn more
    Disclaimer

    Seraccess® is a mid-stage venture project of Securecell that offers investment opportunities to private and institutional investors.

    All information and opinions contained herein have been prepared by management and its advisors and represent their assessment as of January 2022. No representation or warranty, expressed or implied, is given as to the accuracy or completeness of the contents, opinions, or projections expressed herein and no responsibility or liability is accepted. All information videos and contents do not constitute an offer to purchase securities. The website content does not constitute an invitation to buy shares under US or international law.

    Related Articles on Seraccess®

    Seraccess
    Written by: Dagmar Brunner / 2 min read
    SERACCESS® MILESTONE 7B
    February 6, 2023

    Continuous automated blood sampling including glucose measurement in an animal model

    Read more
    Seraccess
    Written by: Dagmar Brunner / 2 min read
    SERACCESS® MILESTONE 7A
    January 7, 2023

    Continuous automated blood sampling based on an animal model

    Read more
    Seraccess
    Written by: Claudia Bortolussi / 3 min read
    SECURECELL PRESENTED SERACCESS AT ATTD CONFERENCE
    January 5, 2022

    SeraMaster Version 2 – Intravenous blood glucose measurement with subjects with type 1 diabetes

    Read more

    MORE PRODUCTS